Building a Cancer Medtech Company the Hard Way: Shaun Bagai on Evidence, Strategy, and Growth

Episode notes

Drug launches in oncology don’t succeed simply because the technology works; they succeed when the evidence is strong enough to change physician behavior. In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Shaun Bagai, CEO of RenovoRx, to discuss the long and uncertain journey of building a medtech company grounded in clinical proof. From turning down medical school to leading a Nasdaq-listed oncology company, Shaun shares how physician feedback reshaped the company’s strategy, why investing in rigorous clinical trials can be a defining leadership decision, and why face-to-face relationships remain essential for market adoption in healthcare. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk.

• The Question Behind the Question - Field Training with Jennifer Muszik47 / 100
• Why the Small Details Reveal Everything About Your CDMO Partner with Frank Sorce46 / 100
• Why Medical Knowledge Isn’t Reaching Patients with Dr. Simon Chowdhury49 / 100
• Timothy Smith on AI, Data, and Drug Discovery at Takeda
• Lessons on Leading Through Uncertainty in Pharma